Veracyte Corp - VCYT Net earnings per share (EPS TTM)

Veracyte, Inc. (VCYT) is integrating ESG standards into molecular cancer analysis, minimizing waste and protecting data. The EPS YoY TTM growth trajectory on the GURU.Markets chart confirms this trend, where the 311.80 mark serves as a key metric. A steady inflow of funds from clinics supports the business, while the global scaling strategy for genomic tests and cloud services increases the company's margins.

Veracyte Corp (VCYT) - Net earnings per share for the last 12 months from 02/11/2024 to 11/14/2026

Veracyte Corp - analytical breakdowns and key metrics (VCYT)

- share price and consensus valuation forecast:

Share Price veracyte.com|VCYT - Analyst Consensus Forecast

- issuer market value details:

Market Capitalization Veracyte Inc|VCYT - Total Company Value

- shareholders' equity book value data:

Net Assets per Single Share Veracyte|VCYT - Company Net Assets|Market-to-Book Ratio veracyte.com|VCYT - Aggregate Company Assets

- debt and liquidity data:

- earnings and valuation multiples indicators:

VCYT - Company Net Income|Expected Net Income Veracyte, Inc.|VCYT - P/E Multiple|Forward P/E Multiple Veracyte Inc|VCYT - PEG Multiple|Enterprise Value to EBITDA Ratio Veracyte Inc|VCYT - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Veracyte|VCYT - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months veracyte.com|VCYT - Earnings growth in current year|Expected net earnings per share growth next year Veracyte, Inc.

- sales volume and revenue information:

VCYT - Company Sales|Company Future Revenue veracyte.com|VCYT - P/S Multiple|Market Cap to Expected Sales Ratio Veracyte Inc

Initial company analysis:VCYT (veracyte.com)

Scaling AI classifiers for the interpretation of Veracyte, Inc. (VCYT) genomic tests directly impacts operational efficiency, which is reflected in the current YoY ttm net income per share growth of 311.80. This metric measures the percentage change in EPS over the last 12 months, allowing investors to confirm real earnings growth and exclude accounting manipulations when assessing asset quality through daily price action.

Direct competitors